LabCorp Announces Record 2017 Fourth Quarter and Full Year Results and Provides 2018 Guidance

Net Revenue: Q4 of $2.7 billion , up 13% over 2016; Full year of $10.2 billion , up 8% over 2016 Diluted EPS: Q4 of $6.81 , up 289% over 2016; Full year of $12.21 , up 74% over 2016 Adjusted EPS: Q4 of $2.45 , up 14% over 2016; Full year of $9.60 , up 9% over 2016 Free Cash Flow: Q4 of $468 million

LabCorp Named to FORTUNE Magazine's 2018 List of ‘World’s Most Admired Companies’

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 19, 2018-- Laboratory Corporation of America ® Holdings (LabCorp) (NYSE: LH), a leading global life sciences company, today announced that it has been named to FORTUNE magazine's 2018 List of World’s Most Admired Companies .

Covance Introduces Dedicated Offering Designed for Biotech, Medical Device and Diagnostics Companies

Distinctive development solutions provided by Chiltern®, a Covance® company BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 8, 2018-- LabCorp® (NYSE: LH), a leading global life sciences company, announced today that its Covance Drug Development (Covance) business has introduced a dedicated offering for

LabCorp is Scheduled to Present at the 36th Annual J.P. Morgan Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 3, 2018-- LabCorp® (NYSE: LH) today announced it will participate at the 36th Annual J.P. Morgan Healthcare Conference . LabCorp’s presentation is scheduled for Tuesday, January 9, 2018 at 9:30 am (PT) . A live audio webcast of the presentation will be

Conversion Right Triggered For LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 2, 2018-- LabCorp ® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject

LabCorp Supports American Clinical Laboratory Association Lawsuit on PAMA Final Rule

Final Rule Establishes Medicare Payment Rates for Clinical Laboratory Tests That Will Harm Beneficiaries and Restrict Access to Necessary Lab Services BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 11, 2017-- LabCorp (NYSE: LH), a leading global life sciences company, today issued the following statement

LabCorp Announces New Expanded Use for PD-L1 Test with Bristol-Myers Squibb’s OPDIVO®

LabCorp Performed Testing for Studies Supporting Approval of Two New Complementary Diagnostic Indications in Connection with the Treatment of Bladder Cancer and Cancer of the Head and Neck BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 15, 2017-- LabCorp (NYSE: LH) a leading global life sciences company,

LabCorp Receives 2017 Partnership Award from Be The Match®

Award Recognizes 25 Years of Innovation and Support to Help Cure Blood Cancers BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 13, 2017-- LabCorp, (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, proudly announces that it received the 2017 Partnership

LabCorp Earns 100 Percent on Human Rights Campaign Foundation’s 16th Annual Scorecard on LGBTQ Workplace Equality

Receives Designation as a Best Place to Work for LGBTQ Equality BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 13, 2017-- LabCorp (NYSE: LH), a leading global life sciences company, announced that it received a perfect score of 100 percent on the 2018 Corporate Equality Index (CEI), a national

LabCorp is Scheduled to Present at the 26th Annual Credit Suisse Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 1, 2017-- LabCorp ® (NYSE: LH) today announced it will participate at the 26th Annual Credit Suisse Healthcare Conference . LabCorp’s presentation is planned for Tuesday, November 7, 2017 at 10:55 am (MT) . A live audio webcast will be available via the